Edition:
United States

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

33.36USD
16 Aug 2017
Change (% chg)

$-0.02 (-0.06%)
Prev Close
$33.38
Open
$33.34
Day's High
$33.48
Day's Low
$33.27
Volume
3,707,450
Avg. Vol
5,627,652
52-wk High
$35.38
52-wk Low
$29.83

Latest Key Developments (Source: Significant Developments)

Soros Fund Management dissolves share stake in Tesla, Pfizer, ConocoPhillips
Monday, 14 Aug 2017 06:15pm EDT 

Aug 14 (Reuters) - Soros Fund Management::Soros Fund Management dissolves share stake in Tesla Inc - SEC filing.Soros Fund Management dissolves share stake in Pfizer Inc.Soros Fund Management dissolves share stake in ConocoPhillips.Soros Fund Management: Change in holdings are as of June 30, 2017 and compared with the previous quarter ended as of March 31, 2017.  Full Article

Paulson & Co dissolves share stake in Pfizer, ups in Valeant ‍​
Monday, 14 Aug 2017 05:12pm EDT 

Aug 14 (Reuters) - Paulson & Co Inc : :Paulson & Co dissolves share stake in Pfizer- SEC filing ‍​.Paulson & Co Inc raises share stake in Valeant Pharmaceuticals by 12.5 percent to 21.8 million shares ‍​.‍Paulson & Co - Change in holdings are as of June 30, 2017 and compared with the previous quarter ended as of March 31, 2017 ​.  Full Article

Appaloosa dissolves share stake in Snap Inc, Pfizer Inc
Monday, 14 Aug 2017 04:41pm EDT 

Aug 14 (Reuters) - Appaloosa Lp::Appaloosa Lp dissolves class a share stake in Snap Inc - SEC Filing.Appaloosa Lp ups share stake in Apple Inc to 625,000 from 300,000.Appaloosa Lp dissolves share stake Pfizer Inc.Appaloosa Lp: change in holdings are as of June 30, 2017 and compared with the previous quarter ended as of March 31, 2017.  Full Article

Pfizer Inc - U.S. DOJ's antitrust division is investigating co's greenstone generics business - SEC Filing‍​
Thursday, 10 Aug 2017 04:47pm EDT 

Aug 10 (Reuters) - Pfizer Inc :Pfizer Inc - as of July 2017, U.S. DOJ's antitrust division is investigating co's greenstone generics business - SEC Filing‍​.  Full Article

Avara Pharmaceutical buys Pfizer's Italy sterile facility
Tuesday, 8 Aug 2017 08:00am EDT 

Aug 8 (Reuters) - Pfizer Inc :Avara Pharmaceutical Services acquires sterile facility from Pfizer in Italy.‍Avara Pharmaceutical Services - signed an agreement with Pfizer Inc to acquire Liscate, Italy sterile manufacturing facility​.  Full Article

BRIEF-Pfizer reports second-quarter results (Aug 1)
Wednesday, 2 Aug 2017 05:54am EDT 

Corrects ninth bullet point to say revenue is for Q2, not Q1:Pfizer reports second-quarter 2017 results.Q2 adjusted earnings per share $0.67.Sees FY 2017 revenue $52 billion to $54 billion.Q2 earnings per share $0.51.Q2 earnings per share view $0.66 -- Thomson Reuters I/B/E/S.Raised midpoint of 2017 adjusted diluted EPS guidance range by $0.02 to a range of $2.54 to $2.60​.Reaffirmed 2017 revenue guidance range of $52.0 to $54.0 billion​.Q2 Innovative Health segment revenue $‍7,671​ million versus $7,105 million.Q2 revenue $‍12,896​ million versus $13,147 million.Second-quarter revenue unfavorably impacted by $295 million due to February 2017 divestiture of Hospira Infusion Systems​.Q2 revenue view $13.08 billion -- Thomson Reuters I/B/E/S.Q2 operational growth was "negatively impacted" by lower revenues for Enbrel in most developed Europe markets​.FY2017 earnings per share view $2.55, revenue view $52.76 billion -- Thomson Reuters I/B/E/S.  Full Article

Pfizer reports Q2 worldwide Ibrance revenue $853 mln vs $514 mln
Tuesday, 1 Aug 2017 09:10am EDT 

Aug 1 (Reuters) - Pfizer Inc :Q2 worldwide Ibrance revenue $853 million versus $514 million.Pfizer Inc - Q2 worldwide total Lyrica revenue $1,254‍​ million versus $1,261 million.Pfizer Inc - Q2 worldwide Lipitor revenue $‍​445 million versus $461 million.Pfizer Inc - qtrly worldwide Prevnar family revenue $1,154 million versus $1,258 million.  Full Article

Pfizer Q2 earnings per share $0.51
Tuesday, 1 Aug 2017 06:45am EDT 

Aug 1 (Reuters) - Pfizer Inc :Pfizer reports second-quarter 2017 results.Q2 revenue $‍12,896​ million versus $13,147 million .Q2 adjusted earnings per share $0.67.Sees fy 2017 revenue $52 billion to $54 billion.Q2 earnings per share $0.51.Q2 earnings per share view $0.66 -- Thomson Reuters I/B/E/S.Raised midpoint of 2017 adjusted diluted eps guidance range by $0.02 to a range of $2.54 to $2.60​.Reaffirmed 2017 revenue guidance range of $52.0 to $54.0 billion​.Q2 innovative health segment revenue $‍7,671​ million versus $7,105 million.Second-quarter revenues unfavorably impacted by $295 million due to february 2017 divestiture of hospira infusion systems​.Q2 revenue view $13.08 billion -- Thomson Reuters I/B/E/S.Q2 operational growth in innovative health segment "negatively impacted" by lower revenues for Enbrel in most developed europe markets​.Fy2017 earnings per share view $2.55, revenue view $52.76 billion -- Thomson Reuters I/B/E/S.  Full Article

Pfizer reports second-quarter results
Tuesday, 1 Aug 2017 06:45am EDT 

Aug 1 (Reuters) - Pfizer Inc :Pfizer reports second-quarter 2017 results.Q2 adjusted earnings per share $0.67.Sees FY 2017 revenue $52 billion to $54 billion.Q2 earnings per share $0.51.Q2 earnings per share view $0.66 -- Thomson Reuters I/B/E/S.Pfizer Inc - ‍raised midpoint of 2017 adjusted diluted EPS guidance range by $0.02 to a range of $2.54 to $2.60​.Pfizer Inc - ‍reaffirmed 2017 revenue guidance range of $52.0 to $54.0 billion​.Pfizer Inc - Q2 innovative health segment revenue $‍7,671​ million versus $7,105 million.Q1 revenue $‍12,896​ million versus $13,147 million.Pfizer Inc - ‍second-quarter revenues unfavorably impacted by $295 million due to february 2017 divestiture of Hospira Infusion Systems​.Q2 revenue view $13.08 billion -- Thomson Reuters I/B/E/S.Pfizer Inc - Q2 operational growth was "negatively impacted" by lower revenues for Enbrel in most developed Europe markets​.FY2017 earnings per share view $2.55, revenue view $52.76 billion -- Thomson Reuters I/B/E/S.  Full Article

GlaxoSmithKline says ViiV announces results from NEAT 022 study
Tuesday, 25 Jul 2017 08:30am EDT 

July 25 (Reuters) - Glaxosmithkline Plc :VIIV HEALTHCARE AND NEAT-ID ANNOUNCED RESULTS FROM NEAT 022 STUDY OF MORE THAN 400 PATIENTS WITH HIV AND HIGH CARDIOVASCULAR RISK.  Full Article